Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AtriCure, Inc.ATRC · Entity 2704 | Director | August 05, 2026 | August 07, 2026 |
| Embecta Corp.EMBC · Entity 5950 | Director | February 11, 2026 | February 13, 2026 |
| HENRY SCHEIN INCHSIC · Entity 3536 | EVP&CEO Gl.AH.Med.Den.Sur.Grp | March 02, 2018 | March 06, 2018 |
| Outset Medical, Inc.OM · Entity 7026 | Director | June 04, 2026 | June 05, 2026 |
| ViewRay, Inc.VRAY · Entity 111118 | Director | July 19, 2023 | July 21, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AtriCure, Inc.
Report date August 05, 2026 · Filed August 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,809 |
Reported balance
After 2026-08-05 transaction · row 1
1 source rowRow 1 · 2026-08-05 · Sale · Disposed 3,564 · Balance 22,809 |
Embecta Corp.
Report date February 11, 2026 · Filed February 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 64,581.208 |
Reported balance
After 2026-02-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-02-11 · Grant · Acquired 22,841 · Balance 64,581.208 F1: The number of shares reported in Column 5 of Table I includes shares received by the reporting person as stock dividends. |
Filing footnotes · ownership attribution and instrument terms
F1: The number of shares reported in Column 5 of Table I includes shares received by the reporting person as stock dividends.
HENRY SCHEIN INC
Report date March 02, 2018 · Filed March 06, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.01 per shareSEC Table I · non-derivative | Direct | 62,902 |
Reported balance
After 2018-03-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-03-02 · Grant · Acquired 19,558 · Balance 62,902 F1: Grant of restricted stock units (RSU) pursuant to the Issuer's 2013 Stock Incentive Plan. Subject to certain exceptions, 65% will vest subject to (x) Issuer's achievement of a specified performance goal and (y) reporting person's continued perf. of services for the Issuer. 35% will vest subject to (x) passage of a specified period of time and (y) reporting person's continued perf. of services for the Issuer. With respect to the performance-based RSU, if the continued service requirement is satisfied and achievement of the performance goal (x) exceeds 100% of target, the Issuer may issue additional vested shares of common stock in an amount that corresponds to the incremental percentage of the performance goal achieved in excess of 100% of target or (y) is less than 100% of target, the reporting person will surrender to the Issuer shares of common stock in an amount that corresponds to the incremental percentage of the performance goal achieved that is below 100% of target (shortfall). F2: On September 14, 2017, the common stock of Henry Schein, Inc. split two-for-one (for shares held on the record date of September 1, 2017), resulting in the reporting person's ownership of additional shares of common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted stock units (RSU) pursuant to the Issuer's 2013 Stock Incentive Plan. Subject to certain exceptions, 65% will vest subject to (x) Issuer's achievement of a specified performance goal and (y) reporting person's continued perf. of services for the Issuer. 35% will vest subject to (x) passage of a specified period of time and (y) reporting person's continued perf. of services for the Issuer. With respect to the performance-based RSU, if the continued service requirement is satisfied and achievement of the performance goal (x) exceeds 100% of target, the Issuer may issue additional vested shares of common stock in an amount that corresponds to the incremental percentage of the performance goal achieved in excess of 100% of target or (y) is less than 100% of target, the reporting person will surrender to the Issuer shares of common stock in an amount that corresponds to the incremental percentage of the performance goal achieved that is below 100% of target (shortfall).
F2: On September 14, 2017, the common stock of Henry Schein, Inc. split two-for-one (for shares held on the record date of September 1, 2017), resulting in the reporting person's ownership of additional shares of common stock.
Outset Medical, Inc.
Report date June 04, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 29,334 |
Reported balance
After 2026-06-04 transaction · row 1
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 10,667 · Balance 29,334 F1: 100% of the shares underlying these RSUs will vest upon the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the Issuer's next Annual Meeting of Stockholders |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares underlying these RSUs will vest upon the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the Issuer's next Annual Meeting of Stockholders
ViewRay, Inc.
Report date July 19, 2023 · Filed July 21, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,799 |
Ending reported balance
After 2023-07-21 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-07-19 · Sale · Disposed 91,866 · Balance 46,399 Row 2 · 2023-07-21 · Sale · Disposed 37,600 · Balance 8,799 |
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CANTEL MEDICAL CORP
Report date June 02, 2021 · Filed June 02, 2021
Section 16 reporting ended · disclosed 2021-06-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $.10 per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-06-02 transaction · row 1
1 source rowRow 1 · 2021-06-02 · Disposition to issuer · Disposed 1,935 · Balance 0 F1: Represents shares that, at the effective time of the First Merger (as defined in the Agreement and Plan of Merger, as amended and restated on March 1, 2021 (the "Merger Agreement"), by and among Cantel Medical Corp., a Delaware corporation (the "Company"), STERIS plc, an Irish public limited company ("STERIS"), Solar New US Holding Co, LLC and Crystal Merger Sub 1, LLC) (the "Effective Time"), were converted into the right to receive (i) 0.33787 ordinary shares, par value $0.001 per share, of STERIS (the "Stock Consideration"), and (ii) $16.93 in cash (the "Cash Consideration" and, together with the Stock Consideration, the "Merger Consideration"). F2: Based on the closing price of ordinaryshares of STERIS on June 1, 2021, the last trading day before the Effective Time, the value of the Stock Consideration payable per share of common stock, parvalue $.10 per share, of the Company ("Company Common Stock") was $63.66, and the value of the Merger Consideration payable per share of CompanyCommon Stock pursuant to the Merger Agreement was $80.59. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares that, at the effective time of the First Merger (as defined in the Agreement and Plan of Merger, as amended and restated on March 1, 2021 (the "Merger Agreement"), by and among Cantel Medical Corp., a Delaware corporation (the "Company"), STERIS plc, an Irish public limited company ("STERIS"), Solar New US Holding Co, LLC and Crystal Merger Sub 1, LLC) (the "Effective Time"), were converted into the right to receive (i) 0.33787 ordinary shares, par value $0.001 per share, of STERIS (the "Stock Consideration"), and (ii) $16.93 in cash (the "Cash Consideration" and, together with the Stock Consideration, the "Merger Consideration").
F2: Based on the closing price of ordinaryshares of STERIS on June 1, 2021, the last trading day before the Effective Time, the value of the Stock Consideration payable per share of common stock, parvalue $.10 per share, of the Company ("Company Common Stock") was $63.66, and the value of the Merger Consideration payable per share of CompanyCommon Stock pursuant to the Merger Agreement was $80.59.
NEVRO CORP
Report date April 03, 2025 · Filed April 03, 2025
Section 16 reporting ended · disclosed 2025-04-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-04-03 transaction · row 1
1 source rowRow 1 · 2025-04-03 · Disposition to issuer · Disposed 33,948 · Balance 0 F1: Pursuant to that certain Agreement and Plan of Merger, dated February 6, 2025, by and among the Issuer, Globus Medical, Inc. ("Globus") and Palmer Merger Sub, Inc., a direct, wholly owned subsidiary of Globus ("Merger Sub"), Merger Sub merged with and into the Issuer, and the Issuer became a wholly owned subsidiary of Globus upon consummation of the merger (the "Effective Time"). F2: At the Effective Time, (i) each outstanding share of Common Stock was automatically converted into the right to receive $5.85 in cash (the "Merger Consideration"), (ii) each outstanding award of restricted stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award and (b) the Merger Consideration, and (iii) each outstanding award of performance stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award, assuming that the applicable performance goals have been achieved at the greater of target and actual level of performance as determined by the compensation committee, and (b) the Merger Consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to that certain Agreement and Plan of Merger, dated February 6, 2025, by and among the Issuer, Globus Medical, Inc. ("Globus") and Palmer Merger Sub, Inc., a direct, wholly owned subsidiary of Globus ("Merger Sub"), Merger Sub merged with and into the Issuer, and the Issuer became a wholly owned subsidiary of Globus upon consummation of the merger (the "Effective Time").
F2: At the Effective Time, (i) each outstanding share of Common Stock was automatically converted into the right to receive $5.85 in cash (the "Merger Consideration"), (ii) each outstanding award of restricted stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award and (b) the Merger Consideration, and (iii) each outstanding award of performance stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award, assuming that the applicable performance goals have been achieved at the greater of target and actual level of performance as determined by the compensation committee, and (b) the Merger Consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 05, 2026 Filed Aug 7, 2026 13:18 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 3,564 | $38.80 | $138,283.20 |
DisclosureSEC source: 0001566083-26-000006 · wk-form4_1786108718.xml · nonDerivative · entry 1 Prange Karen · CIK 0001566083 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,809 Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 22:11 UTC | Outset Medical, Inc. OM · Entity 7026 | GrantCommon Stock | 10,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001484612-26-000034 · edgardoc.xml · nonDerivative · entry 1 Prange Karen · CIK 0001566083 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,334 F1 · shares: 100% of the shares underlying these RSUs will vest upon the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the Issuer's next Annual Meeting of Stockholders Read SEC document |
| May 20, 2026 Filed May 22, 2026 12:57 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 3,000 | $28.65 | $85,950.00 |
DisclosureSEC source: 0001566083-26-000004 · wk-form4_1779454631.xml · nonDerivative · entry 1 Prange Karen · CIK 0001566083 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,373 F1 · price: This transaction was executed in multiple trades at prices ranging from $28.60 to $28.76 per share. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 18, 2026 Filed May 20, 2026 16:44 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 6,144 | $0.00 | $0.00 |
DisclosureSEC source: 0001566083-26-000002 · wk-form4_1779295456.xml · nonDerivative · entry 1 Prange Karen · CIK 0001566083 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,373 F1 · shares: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 23:25 UTC | Embecta Corp. EMBC · Entity 5950 | GrantCommon Stock | 22,841 | $0.00 | $0.00 |
DisclosureSEC source: 0000947871-26-000162 · ownership.xml · nonDerivative · entry 1 Prange Karen · CIK 0001566083 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,581.208 F1 · balance_after: The number of shares reported in Column 5 of Table I includes shares received by the reporting person as stock dividends. Read SEC document |
| January 09, 2026 Filed Jan 12, 2026 21:25 UTC | Outset Medical, Inc. OM · Entity 7026 | GrantCommon Stock | 18,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001484612-26-000007 · edgardoc.xml · nonDerivative · entry 1 Prange Karen · CIK 0001566083 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,667 F1 · shares: Represents Restricted Stock Units ("RSUs") granted to the reporting person on January 9, 2026. Each RSU represents a contingent right to receive one share of common stock. These RSUs shall vest quarterly over three years, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| May 19, 2025 Filed May 21, 2025 20:42 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 5,401 | $0.00 | $0.00 |
DisclosureSEC source: 0001323885-25-000063 · wk-form4_1747860154.xml · nonDerivative · entry 1 Prange Karen · CIK 0001566083 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,229 F1 · shares: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date. Read SEC document |
| April 03, 2025 Filed Apr 3, 2025 16:30 UTC | NEVRO CORP NVRO · Entity 12422 | Disposition to issuerCommon Stock | 33,948 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-050472 · ownership.xml · nonDerivative · entry 1 Prange Karen · CIK 0001566083 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to that certain Agreement and Plan of Merger, dated February 6, 2025, by and among the Issuer, Globus Medical, Inc. ("Globus") and Palmer Merger Sub, Inc., a direct, wholly owned subsidiary of Globus ("Merger Sub"), Merger Sub merged with and into the Issuer, and the Issuer became a wholly owned subsidiary of Globus upon consummation of the merger (the "Effective Time"). F2 · price: At the Effective Time, (i) each outstanding share of Common Stock was automatically converted into the right to receive $5.85 in cash (the "Merger Consideration"), (ii) each outstanding award of restricted stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award and (b) the Merger Consideration, and (iii) each outstanding award of performance stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award, assuming that the applicable performance goals have been achieved at the greater of target and actual level of performance as determined by the compensation committee, and (b) the Merger Consideration. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 13:21 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 6,100 | $38.12 | $232,532.00 |
DisclosureSEC source: 0001323885-25-000027 · wk-form4_1741353680.xml · nonDerivative · entry 1 Prange Karen · CIK 0001566083 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,828 F1 · price: This transaction was executed in multiple trades at prices ranging from $37.60 to $38.52 per share. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 23:26 UTC | Embecta Corp. EMBC · Entity 5950 | GrantCommon Stock | 13,839 | $0.00 | $0.00 |
DisclosureSEC source: 0000947871-25-000188 · ownership.xml · nonDerivative · entry 1 Prange Karen · CIK 0001566083 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,743.197 F1 · balance_after: The number of shares reported in Column 5 of Table I includes shares received by the reporting person as stock dividends. Read SEC document |
| May 23, 2024 Filed May 28, 2024 18:55 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 19,169 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000263 · form4.xml · nonDerivative · entry 1 Prange Karen · CIK 0001566083 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,948 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) one year anniversary of May 23, 2024 or (ii) the next Annual Meeting following May 23, 2024, subject to the Reporting Person's continued service to the Issuer. F2 · balance_after: Includes 19,169 RSUs. Read SEC document |
| May 13, 2024 Filed May 14, 2024 21:04 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 7,788 | $0.00 | $0.00 |
DisclosureSEC source: 0001323885-24-000078 · wk-form4_1715720654.xml · nonDerivative · entry 1 Prange Karen · CIK 0001566083 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,928 F1 · shares: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date. Read SEC document |
| February 07, 2024 Filed Feb 9, 2024 23:08 UTC | Embecta Corp. EMBC · Entity 5950 | GrantCommon Stock | 11,455 | $0.00 | $0.00 |
DisclosureSEC source: 0000947871-24-000106 · ownership.xml · nonDerivative · entry 1 Prange Karen · CIK 0001566083 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,897.902 F1 · balance_after: The number of shares reported in Column 5 of Table I includes shares received by the reporting person as stock dividends. Read SEC document |
| July 21, 2023 Filed Jul 21, 2023 20:02 UTC | ViewRay, Inc. VRAY · Entity 111118 | SaleCommon Stock | 37,600 | $0.05 | $1,917.60 |
DisclosureSEC source: 0001628280-23-025327 · wk-form4_1689969730.xml · nonDerivative · entry 2 Prange Karen · CIK 0001566083 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,799 Read SEC document |
| July 19, 2023 Filed Jul 21, 2023 20:02 UTC | ViewRay, Inc. VRAY · Entity 111118 | SaleCommon Stock | 91,866 | $0.08 | $6,889.95 |
DisclosureSEC source: 0001628280-23-025327 · wk-form4_1689969730.xml · nonDerivative · entry 1 Prange Karen · CIK 0001566083 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,399 Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 12:59 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 713 | $47.89 | $34,145.57 |
DisclosureSEC source: 0001323885-23-000075 · wk-form4_1686574751.xml · nonDerivative · entry 1 Prange Karen · CIK 0001566083 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,140 Read SEC document |
| May 25, 2023 Filed May 26, 2023 20:25 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 3,186 | $0.00 | $0.00 |
DisclosureSEC source: 0001323885-23-000065 · wk-form4_1685132734.xml · nonDerivative · entry 1 Prange Karen · CIK 0001566083 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,853 F1 · shares: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date. Read SEC document |
| May 25, 2023 Filed May 30, 2023 17:15 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 6,754 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-23-000074 · form4.xml · nonDerivative · entry 1 Prange Karen · CIK 0001566083 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,779 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) one year anniversary of May 25, 2023 or (ii) the next Annual Meeting following May 25, 2023, subject to the Reporting Person's continued service to the Issuer. F2 · balance_after: Includes 6,754 RSUs. Read SEC document |
| February 09, 2023 Filed Feb 10, 2023 21:09 UTC | Embecta Corp. EMBC · Entity 5950 | GrantCommon Stock | 6,979 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-008327 · doc4.xml · nonDerivative · entry 1 Prange Karen · CIK 0001566083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,068.8229 F1 · balance_after: The number of shares reported in Column 5 of Table I now includes 65.822912 shares received by the reporting person as stock dividends. Read SEC document |
| June 13, 2022 Filed Jun 15, 2022 20:09 UTC | ViewRay, Inc. VRAY · Entity 111118 | GrantCommon Stock | 54,511 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-017225 · wf-form4_165532375303884.xml · nonDerivative · entry 1 Prange Karen · CIK 0001566083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,265 F1 · shares: The reported securities are RSUs that entitle the Reporting Person to receive one share of Common Stock per RSU upon vesting. All of these RSUs shall vest on June 13, 2023, subject to the Reporting Person remaining a service provider through such date. Read SEC document |
| May 26, 2022 Filed May 27, 2022 20:59 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 4,155 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-011887 · doc1.xml · nonDerivative · entry 1 Prange Karen · CIK 0001566083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,025 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) one year anniversary of May 26, 2022 or (ii) the next Annual Meeting following May 26, 2022, subject to the Reporting Person's continued service to the issuer. F2 · balance_after: Includes 5,056 RSUs. Read SEC document |
| May 25, 2022 Filed May 27, 2022 13:03 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 3,564 | $0.00 | $0.00 |
DisclosureSEC source: 0001323885-22-000074 · wf-form4_165365659896970.xml · nonDerivative · entry 1 Prange Karen · CIK 0001566083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,667 F1 · shares: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2014 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date. Read SEC document |
| May 10, 2022 Filed May 12, 2022 10:05 UTC | ViewRay, Inc. VRAY · Entity 111118 | PurchaseCommon Stock | 26,300 | $2.66 | $69,958.00 |
DisclosureSEC source: 0001628280-22-013939 · wf-form4_165234990590541.xml · nonDerivative · entry 3 Prange Karen · CIK 0001566083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,754 Read SEC document |
| May 10, 2022 Filed May 12, 2022 10:05 UTC | ViewRay, Inc. VRAY · Entity 111118 | PurchaseCommon Stock | 10,000 | $2.66 | $26,592.00 |
DisclosureSEC source: 0001628280-22-013939 · wf-form4_165234990590541.xml · nonDerivative · entry 2 Prange Karen · CIK 0001566083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,454 Read SEC document |
| May 10, 2022 Filed May 12, 2022 10:05 UTC | ViewRay, Inc. VRAY · Entity 111118 | PurchaseCommon Stock | 1,300 | $2.66 | $3,451.50 |
DisclosureSEC source: 0001628280-22-013939 · wf-form4_165234990590541.xml · nonDerivative · entry 1 Prange Karen · CIK 0001566083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,454 Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 21:38 UTC | Embecta Corp. EMBC · Entity 5950 | GrantCommon Stock | 6,024 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-023212 · doc4.xml · nonDerivative · entry 1 Prange Karen · CIK 0001566083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,024 Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 20:32 UTC | ViewRay, Inc. VRAY · Entity 111118 | GrantCommon Stock | 26,395 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-045486 · doc4.xml · nonDerivative · entry 1 Prange Karen · CIK 0001566083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,154 F1 · shares: These shares are RSUs and 1/36th of the RSUs shall vest on each monthly anniversary measured from July 1, 2021 (the "Vesting Commencement Date"), such that 100% of the RSUs will be fully vested on the third anniversary of the Vesting Commencement Date, subject to the Reporting Person remaining a service provider through each such vesting date. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 20:25 UTC | ViewRay, Inc. VRAY · Entity 111118 | GrantCommon Stock | 19,759 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-040912 · doc4.xml · nonDerivative · entry 1 Prange Karen · CIK 0001566083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,759 F1 · shares: The reported securities are RSUs that entitle the Reporting Person to receive one share of Common Stock per RSU upon vesting. All of these RSUs shall vest on June 14, 2022, subject to the Reporting Person remaining a service provider through such date. Read SEC document |
| June 02, 2021 Filed Jun 2, 2021 17:27 UTC | CANTEL MEDICAL CORP CMD · Entity 138805 | Disposition to issuerCommon Stock, par value $.10 per share | 1,935 | $80.59 | $155,941.65 |
DisclosureSEC source: 0001104659-21-075860 · tm2118222-14_4seq1.xml · nonDerivative · entry 1 Prange Karen · CIK 0001566083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Represents shares that, at the effective time of the First Merger (as defined in the Agreement and Plan of Merger, as amended and restated on March 1, 2021 (the "Merger Agreement"), by and among Cantel Medical Corp., a Delaware corporation (the "Company"), STERIS plc, an Irish public limited company ("STERIS"), Solar New US Holding Co, LLC and Crystal Merger Sub 1, LLC) (the "Effective Time"), were converted into the right to receive (i) 0.33787 ordinary shares, par value $0.001 per share, of STERIS (the "Stock Consideration"), and (ii) $16.93 in cash (the "Cash Consideration" and, together with the Stock Consideration, the "Merger Consideration"). F2 · kind: Based on the closing price of ordinaryshares of STERIS on June 1, 2021, the last trading day before the Effective Time, the value of the Stock Consideration payable per share of common stock, parvalue $.10 per share, of the Company ("Company Common Stock") was $63.66, and the value of the Merger Consideration payable per share of CompanyCommon Stock pursuant to the Merger Agreement was $80.59. F1 · shares: Represents shares that, at the effective time of the First Merger (as defined in the Agreement and Plan of Merger, as amended and restated on March 1, 2021 (the "Merger Agreement"), by and among Cantel Medical Corp., a Delaware corporation (the "Company"), STERIS plc, an Irish public limited company ("STERIS"), Solar New US Holding Co, LLC and Crystal Merger Sub 1, LLC) (the "Effective Time"), were converted into the right to receive (i) 0.33787 ordinary shares, par value $0.001 per share, of STERIS (the "Stock Consideration"), and (ii) $16.93 in cash (the "Cash Consideration" and, together with the Stock Consideration, the "Merger Consideration"). F2 · shares: Based on the closing price of ordinaryshares of STERIS on June 1, 2021, the last trading day before the Effective Time, the value of the Stock Consideration payable per share of common stock, parvalue $.10 per share, of the Company ("Company Common Stock") was $63.66, and the value of the Merger Consideration payable per share of CompanyCommon Stock pursuant to the Merger Agreement was $80.59. F1 · price: Represents shares that, at the effective time of the First Merger (as defined in the Agreement and Plan of Merger, as amended and restated on March 1, 2021 (the "Merger Agreement"), by and among Cantel Medical Corp., a Delaware corporation (the "Company"), STERIS plc, an Irish public limited company ("STERIS"), Solar New US Holding Co, LLC and Crystal Merger Sub 1, LLC) (the "Effective Time"), were converted into the right to receive (i) 0.33787 ordinary shares, par value $0.001 per share, of STERIS (the "Stock Consideration"), and (ii) $16.93 in cash (the "Cash Consideration" and, together with the Stock Consideration, the "Merger Consideration"). F2 · price: Based on the closing price of ordinaryshares of STERIS on June 1, 2021, the last trading day before the Effective Time, the value of the Stock Consideration payable per share of common stock, parvalue $.10 per share, of the Company ("Company Common Stock") was $63.66, and the value of the Merger Consideration payable per share of CompanyCommon Stock pursuant to the Merger Agreement was $80.59. Read SEC document |
| May 25, 2021 Filed May 26, 2021 21:01 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 1,167 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-011223 · doc1.xml · nonDerivative · entry 1 Prange Karen · CIK 0001566083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,870 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) one year anniversary of May 25, 2021 or (ii) the next Annual Meeting following May 25, 2021, subject to the Reporting Person's continued service to the issuer. F2 · balance_after: Includes 2,969 RSUs. Read SEC document |
| May 20, 2021 Filed May 24, 2021 20:52 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 1,749 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-035362 · doc4.xml · nonDerivative · entry 1 Prange Karen · CIK 0001566083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,103 F1 · shares: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2014 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date. Read SEC document |
| July 31, 2020 Filed Jul 31, 2020 17:53 UTC | CANTEL MEDICAL CORP CMD · Entity 138805 | GrantCommon Stock, par value $.10 per share | 1,935 | $0.00 | $0.00 |
DisclosureSEC source: 0000019446-20-000042 · wf-form4_159623241881673.xml · nonDerivative · entry 1 Prange Karen · CIK 0001566083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,935 Read SEC document |
| May 20, 2020 Filed May 22, 2020 12:28 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 2,452 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-031562 · doc4.xml · nonDerivative · entry 1 Prange Karen · CIK 0001566083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,354 F1 · shares: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2014 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date. Read SEC document |
| December 17, 2019 Filed Dec 18, 2019 16:31 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 2,703 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-023321 · doc1.xml · nonDerivative · entry 1 Prange Karen · CIK 0001566083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,703 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3 of the RSUs vest annually on December 17 of each year, beginning December 17, 2020, subject to the Reporting Person's continued service to the issuer. F2 · balance_after: Includes 2,703 RSUs. Read SEC document |
| December 04, 2019 Filed Dec 5, 2019 21:24 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 5,902 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-059298 · doc4.xml · nonDerivative · entry 1 Prange Karen · CIK 0001566083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,902 F1 · price: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2014 Stock Incentive Plan. The shares will vest 33% annually over three years from date of grant. Read SEC document |
| March 02, 2018 Filed Mar 6, 2018 21:23 UTC | HENRY SCHEIN INC HSIC · Entity 3536 | GrantCommon Stock, par value $0.01 per share | 19,558 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-017240 · doc4.xml · nonDerivative · entry 1 Prange Karen · CIK 0001566083 · EVP&CEO Gl.AH.Med.Den.Sur.Grp 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,902 F1 · shares: Grant of restricted stock units (RSU) pursuant to the Issuer's 2013 Stock Incentive Plan. Subject to certain exceptions, 65% will vest subject to (x) Issuer's achievement of a specified performance goal and (y) reporting person's continued perf. of services for the Issuer. 35% will vest subject to (x) passage of a specified period of time and (y) reporting person's continued perf. of services for the Issuer. With respect to the performance-based RSU, if the continued service requirement is satisfied and achievement of the performance goal (x) exceeds 100% of target, the Issuer may issue additional vested shares of common stock in an amount that corresponds to the incremental percentage of the performance goal achieved in excess of 100% of target or (y) is less than 100% of target, the reporting person will surrender to the Issuer shares of common stock in an amount that corresponds to the incremental percentage of the performance goal achieved that is below 100% of target (shortfall). F2 · balance_after: On September 14, 2017, the common stock of Henry Schein, Inc. split two-for-one (for shares held on the record date of September 1, 2017), resulting in the reporting person's ownership of additional shares of common stock. Read SEC document |
| March 06, 2017 Filed Mar 8, 2017 21:25 UTC | HENRY SCHEIN INC HSIC · Entity 3536 | GrantCommon Stock, par value $0.01 per share | 8,777 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-019260 · doc4.xml · nonDerivative · entry 1 Prange Karen · CIK 0001566083 · EVP&CEO Gl.AH.Med.Den.Sur.Grp 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,672 F1 · shares: Grant of restricted stock (RS) pursuant to the Issuer's 2013 Stock Incentive Plan. Subject to certain exceptions, 65% will vest subject to (x) Issuer's achievement of a specified performance goal and (y) reporting person's continued perf. of services for the Issuer. 35% will vest subject to (x) passage of a specified period of time and (y) reporting person's continued perf. of services for the Issuer. With respect to the performance-based RS, if the continued service requirement is satisfied and achievement of the performance goal (x) exceeds 100% of target, the Issuer may issue additional vested shares of common stock in an amount that corresponds to the incremental percentage of the performance goal achieved in excess of 100% of target or (y) is less than 100% of target, the reporting person will surrender to the Issuer shares of common stock in an amount that corresponds to the incremental percentage of the performance goal achieved that is below 100% of target (i.e., shortfall). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.